HNSA Stock Overview
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Hansa Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr27.20 |
| 52 Week High | kr58.10 |
| 52 Week Low | kr20.14 |
| Beta | 1.26 |
| 1 Month Change | -6.21% |
| 3 Month Change | -15.00% |
| 1 Year Change | -43.50% |
| 3 Year Change | -84.19% |
| 5 Year Change | -84.94% |
| Change since IPO | 147.27% |
Recent News & Updates
Recent updates
Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates
Apr 05
Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report
Feb 07Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing
Dec 28Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts
Oct 13Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?
Sep 22Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)
May 31Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt
Apr 03Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Feb 06Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023
Feb 01Shareholder Returns
| HNSA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -6.4% | 2.5% | -0.7% |
| 1Y | -43.5% | -3.4% | 4.4% |
Return vs Industry: HNSA underperformed the Swedish Biotechs industry which returned -5.3% over the past year.
Return vs Market: HNSA underperformed the Swedish Market which returned 10.3% over the past year.
Price Volatility
| HNSA volatility | |
|---|---|
| HNSA Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: HNSA's share price has been volatile over the past 3 months.
Volatility Over Time: HNSA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 166 | Søren Tulstrup | www.hansabiopharma.com |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.
Hansa Biopharma AB (publ) Fundamentals Summary
| HNSA fundamental statistics | |
|---|---|
| Market cap | kr1.50b |
| Earnings (TTM) | -kr844.88m |
| Revenue (TTM) | kr165.88m |
9.0x
P/S Ratio-1.8x
P/E RatioIs HNSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HNSA income statement (TTM) | |
|---|---|
| Revenue | kr165.88m |
| Cost of Revenue | kr71.66m |
| Gross Profit | kr94.23m |
| Other Expenses | kr939.10m |
| Earnings | -kr844.88m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 18, 2024
| Earnings per share (EPS) | -15.35 |
| Gross Margin | 56.80% |
| Net Profit Margin | -509.33% |
| Debt/Equity Ratio | -247.8% |
How did HNSA perform over the long term?
See historical performance and comparison